| 7.84 Real-Time Quote |  -0.04 / -0.51%Today’s Change | 4.41 Today|||52-Week Range 8.50 | +64.02% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $377.2M |
Company Description
Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA.
Employees
Shareholders
| Individual stakeholders | 27.56% |
| Other institutional | 26.66% |
| Mutual fund holders | 16.79% |
Top Executives
| Jeffrey L. Stein, PhD | President, Chief Executive Officer & Director |
| John P. Schmid, MBA | Chief Financial Officer & Secretary |
| John Finn, PhD | Chief Scientific Officer |
| Philippe G. Prokocimer, MD, PhD | Chief Medical Officer |
| Michael Morneau, MBA, CPA | Chief Accounting Officer & Vice President |
.
